FDA Extends Review of Rocket Pharma's Proposed Kresladi
By Colin Kellaher
Rocket Pharmaceuticals on Tuesday said the U.S. Food and Drug Administration has extended its review of the biotechnology company's application seeking approval of its proposed treatment of a rare pediatric immunodeficiency disorder.
Rocket said the FDA extended its target action date for a decision on marnetegragene autotemcel in severe leukocyte adhesion deficiency-I to June 30 from March 31 after the Cranbury, N.J., company submitted clarifying chemistry, manufacturing and controls) information in response to requests from the agency.
Rocket said the FDA confirmed that it won't hold an advisory committee meeting on the application for marnetegragene autotemcel, which the company plans to market as Kresladi.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2024 07:41 ET (12:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks